Caidya and Simbec-Orion Unite to Form a Differentiated Global CRO Spanning First-in-Human to Registration
核心洞察
Caidya (搜索) and Simbec-Orion (搜索) have completed a strategic combination, creating a differentiated global CRO supporting biopharma innovators from First-in-Human through registration.
The combined organization brings together dMed (搜索), Clinipace (搜索) and Simbec-Orion (搜索), with deep regional roots in Asia, the United States and Europe, including substantial clinical trial experience in China.
Caidya (搜索) plans to deepen expertise in oncology, hematology, rare and orphan diseases, cell and gene therapy, CNS and cardio-metabolic interventions over a five-year horizon.
Caidya (搜索) and Simbec-Orion (搜索) have united to form a differentiated global clinical research organization (CRO) that supports biopharma companies across the full clinical development journey, from First-in-Human through global clinical development and registration. Barbara Lopez Kunz, Chief Executive Officer of Caidya, described the combination as a defining milestone for 2026, noting that it "significantly enhances our ability to serve as an agile, end-to-end drug development partner" for biotech and biopharma companies advancing novel and innovative treatments.
The strategic combination brings together three organizations — dMed (搜索), Clinipace (搜索) and Simbec-Orion (搜索) — with deep roots in Asia, the United States and Europe, respectively. According to Lopez Kunz, sponsors gain direct access to experienced local teams, regional expertise and seamless coordination across major research markets, including significant experience conducting trials in China to serve the global market.
A Two-Way Bridge Across Global Markets
Caidya (搜索)'s Asian presence was built through long-standing local operations rather than a remote or partner-only model. The company's heritage includes dMed (搜索), founded in China in 2016, and its 2021 combination with Clinipace (搜索), which created a drug development partner with deep roots in Asia, the United States and Europe.
Today, Caidya (搜索) conducts studies across major Asia-Pacific (APAC) markets. In China, its substantial local team provides regulatory, clinical operations, project management, medical, pharmacovigilance, data management and biostatistics services. Local leadership combines multinational biopharma experience with knowledge of China's regulatory, clinical and cultural environment.
Lopez Kunz framed this infrastructure as a two-way bridge: helping Asian biotechnology companies build globally ready programmes and expand into the United States and Europe, while helping international sponsors incorporate APAC markets into globally synchronised development strategies. "Our model combines consistent global standards with teams that understand local investigators, institutions, regulations and patient pathways," she said.
China's Growing Role in Early-Stage Innovation
China is central to Caidya (搜索)'s APAC opportunity. Recent reports indicate that more than a third of the global early-stage drug pipeline now originates in China, highlighting the country's growing importance to biopharmaceutical innovation. Chinese regulators are also working to accelerate clinical development, with a new pathway that may shorten IND reviews for eligible innovative therapies to 30 working days, making it easier to include China earlier in global programmes.
However, Lopez Kunz cautioned that large patient populations and faster reviews do not eliminate operational complexity. Sponsors must plan early for investigator engagement, ethics review, site readiness, contracts, data and biological-material requirements, and risk management. "Success in APAC requires local knowledge and globally consistent execution," she said.
Five-Year Growth Strategy and Therapeutic Focus
Caidya (搜索)'s five-year strategy is centered on disciplined, sustainable growth rather than scale for its own sake. The company plans to strengthen its position as an agile drug development partner for innovative biotech and biopharma companies advancing scientifically and operationally complex therapies.
A central priority is engaging sponsors early and supporting them throughout the development lifecycle for complex trials. By integrating clinical pharmacology, laboratory services, medical and regulatory strategy, and global clinical execution, Caidya (搜索) aims to help clients make better, faster decisions from first-in-human studies through registration. Lopez Kunz noted that high retention rates allow sponsors to work with consistent teams, processes and quality standards that preserve knowledge and momentum as programmes progress.
In parallel, the company will deepen its expertise in oncology, hematology, rare and orphan diseases, cell and gene therapy, CNS and cardio-metabolic interventions. Success, according to Lopez Kunz, will be measured by enduring partnerships, successful programme progression and the ability to help sponsors reach critical milestones efficiently.
AI and Emerging Technologies in Clinical Development
Lopez Kunz observed that AI is rapidly moving from experimentation to practical implementation across clinical development, with its greatest near-term value lying in helping teams identify risks earlier, analyse complex information more efficiently, and make better-informed decisions. Across the industry, AI is increasingly applied to protocol and indication planning, feasibility, patient population analysis, site selection, recruitment forecasting, risk-based oversight, data review and operational analytics.
Caidya (搜索) collaborates with leading technology partners, including Medidata, to incorporate AI-powered insights into clinical trial management. Through Simbec-Orion (搜索)'s relationship with biotx.ai (搜索), sponsors can leverage causal modeling to support earlier decisions around indications, biomarkers, endpoints and patient selection. The company has also developed a growing portfolio of internal AI solutions supporting clinical operations and business functions, including biometrics, pharmacovigilance processing, medical writing and HR recruitment.
Cell and Gene Therapy Accessibility in Asia
Caidya (搜索) helps sponsors incorporate APAC countries into cell and gene therapy programmes earlier and more strategically, including feasibility and patient-pathway analysis, regulatory planning, qualified-site identification and preparation, investigator engagement, safety oversight and specialised operational coordination.
These trials may require complex manufacturing schedules, time-sensitive transportation, chain-of-identity and chain-of-custody controls, specialised storage, intensive monitoring and long-term follow-up. Caidya (搜索) has experience with autologous and allogeneic cell therapies, including CAR-T programmes, and viral-vector-based gene therapies. "Accessibility begins with making clinical development more geographically inclusive," Lopez Kunz said, noting that opening appropriate APAC sites, preparing institutions, reducing patient burden and incorporating regional data into global programmes can expand trial participation and help build the evidence needed for future approvals.
Complexity in Oncology and Rare Disease Trials
Lopez Kunz highlighted that oncology and rare disease trials are increasingly complex because scientific and operational decisions are closely interconnected. In oncology, biomarker-defined populations, combination therapies, dose optimisation and advanced modalities require early alignment across translational science, regulatory strategy, diagnostics, site selection and clinical operations.
Rare disease trials face different challenges, including small and geographically dispersed patient populations, limited natural-history data, uncertain endpoints, and substantial burdens on patients and caregivers. Success requires understanding the patient journey, engaging investigators and advocacy organisations early, and using flexible approaches that make participation more accessible.
Asia offers innovative science, specialist investigators and sophisticated institutions, but each market has distinct regulatory requirements, diagnostic pathways, standards of care and site-readiness considerations. Lopez Kunz emphasised that globally synchronised development — aligning protocols, regulatory planning and site preparation from the outset — can expand patient access and data diversity without creating sequential delays.